Poppins, a health technology company, has raised €8 million. Along with Verve Ventures, Allianz France, and HEC Ventures, Eurazeo is the lead investor in this round. The company now has a total of €12.9 million in investment.
Additionally included in the fundraising are Kurma Partners, BNP Paribas Développement, and Bpifrance, who have historically held shares of the company.
The company, which launched in 2018 and was spun off from École Polytechnique, is committed to treating neurodevelopmental problems in children. It recently introduced a therapeutic program for families of kids who have specific “dys” intellectual disabilities, such as dyslexia, dysorthography, and dyscalculia.
Such illnesses afflict 7 million people in France. These diseases, which frequently become apparent too late, have impacts on a child’s social, academic, and psychological development and wellbeing.
Read also – UK-based Beta Bugs Secures £1.72M in Funding
Children aged 7 to 11 with one or more particular learning challenges can utilize Poppins’ musical video game, a sort of digital therapy, independently at home. It can be installed to tablets or smartphones.
According to Prof. David Cohen, Head of the Child and Adolescent Psychiatry Department at the Pitié-Salpêtrière Hospital, Paris, the medical device, evaluated at home in a double-blind, randomised placebo-controlled trial, “reinforces the accessibility of care for these young patients. It is an invaluable complement to the usual care pathways.”
Poppins was previously only accessible to people with supplemental health insurance plans that pay for digital therapy.
Read also – Medtech Company Homed-IQ Secures €1M in Funding
After successfully testing the medical instrument with 8,000 Allianz France employees whose children, aged 7 to 11, suffer from specific learning difficulties, Allianz France has acquired an interest in Poppins through its InnovAllianz strategic investment fund.
Mila is a social technology startup that wants to help people via music. Our flagship product is a learning and language disability rehabilitation tool that we create in association with speech therapists and neurologists.